This article is more than 5 years old. Information may no longer be current.

Actavis, Allergan announce SEC declaration, shareholder meetings on pending acquisition

Actavis and Allergan announced that the U.S. Securities and Exchange Commission has declared Actavis’ registration statement on Form S-4 with regard to Actavis’ pending acquisition of Allergan to be effective.

The two companies also announced in a press release that they have scheduled special shareholder meetings on March 10 in connection with the pending acquisition.

The Actavis shareholder meeting will be held in Dublin, Ireland, and the Allergan stockholders are scheduled to meet in Irvine, Calif. Actavis shareholders and Allergan stockholders of record on the close of business Jan. 22 are entitled to vote at the meetings, according to the release.

A joint proxy/statement containing information for the shareholders and stockholders of both companies, along with voting instructions, is expected to be mailed in the upcoming days, the release stated.

Reference: www.actavis.com, www.allergan.com.